TY - JOUR
T1 - Autologous serum eye drops for the treatment of dry eye diseases
AU - Kojima, Takashi
AU - Higuchi, Akihiro
AU - Goto, Eiki
AU - Matsumoto, Yukihiro
AU - Dogru, Murat
AU - Tsubota, Kazuo
PY - 2008/9
Y1 - 2008/9
N2 - Conventional treatment of dry eye mainly consists of the use of preservative-free artificial eye drops and punctal occlusion. None of the commercially available artificial tear preparations include essential tear components such as epidermal growth factor, hepatocyte growth factor, fibronectin, neurotrophic growth factor, and vitamin A-all of which have been shown to play important roles in the maintenance of a healthy ocular surface epithelial milieu. We reported previously that autologous serum (AS) eye drops contain these essential factors and that AS eye drops are beneficial in the treatment of ocular surface diseases such as persistent epithelial defects, superior limbic keratoconjunctivitis, keratoconjunctivitis sicca, and neurotrophic keratopathy. However, there is some controversy regarding the efficacy of AS treatment. We demonstrated that this modality is more effective than artificial tears in a randomized control study. In in vivo and in vitro experiments, AS eye drops showed marked suppression of apoptosis in the conjunctival and corneal epithelium. Albumin, the major protein in serum, improved ocular surface damage in vivo and rescued apoptosis after serum deprivation in vitro. The biological background of AS eye drops and previous clinical studies of these medications for the treatment of dry eye are discussed.
AB - Conventional treatment of dry eye mainly consists of the use of preservative-free artificial eye drops and punctal occlusion. None of the commercially available artificial tear preparations include essential tear components such as epidermal growth factor, hepatocyte growth factor, fibronectin, neurotrophic growth factor, and vitamin A-all of which have been shown to play important roles in the maintenance of a healthy ocular surface epithelial milieu. We reported previously that autologous serum (AS) eye drops contain these essential factors and that AS eye drops are beneficial in the treatment of ocular surface diseases such as persistent epithelial defects, superior limbic keratoconjunctivitis, keratoconjunctivitis sicca, and neurotrophic keratopathy. However, there is some controversy regarding the efficacy of AS treatment. We demonstrated that this modality is more effective than artificial tears in a randomized control study. In in vivo and in vitro experiments, AS eye drops showed marked suppression of apoptosis in the conjunctival and corneal epithelium. Albumin, the major protein in serum, improved ocular surface damage in vivo and rescued apoptosis after serum deprivation in vitro. The biological background of AS eye drops and previous clinical studies of these medications for the treatment of dry eye are discussed.
KW - Autologous serum
KW - Dry eye
KW - Eye drops
UR - http://www.scopus.com/inward/record.url?scp=58149260591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149260591&partnerID=8YFLogxK
U2 - 10.1097/ICO.0b013e31817f3a0e
DO - 10.1097/ICO.0b013e31817f3a0e
M3 - Article
C2 - 18813071
AN - SCOPUS:58149260591
VL - 27
SP - S25-S30
JO - Cornea
JF - Cornea
SN - 0277-3740
IS - SUPPL. 1
ER -